Read this company snapshot
Daily valuation snapshot
Cellectis S.A. American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.26
- Market capitalization (USD)
- $91,147,695.66
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.2
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CLLS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CLLS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CLLS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.26 |
| Market capitalization (USD) | $91,147,695.66 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.2 |
No matching rows. Clear the filter to see all records.
Read CLLS's valuation metrics
Company size
Cellectis S.A. American Depositary Shares's recorded market capitalization is $91,147,695.66. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CLLS's recorded price-to-book ratio is 1.2. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Cellectis S.A. American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about CLLS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CLLS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.